0RA2.L - Poxel S.A.
| Previous close | 1.6000 |
| Open | 5.6442 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.6000 - 1.6000 |
| 52-week range | 1.6000 - 1.6000 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 394,955 |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WirePoxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update
LYON, France, May 17, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.
Business WirePoxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023
LYON, France, May 16, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at 9 am CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bon
Business WirePoxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales
LYON, France, May 15, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced TWYMEEG® (Imeglimin) Fiscal Year (FY) and fourth quarter 2022 results, as recently published by Sumitomo Pharma (Sumitomo), its partner commercializing TWYMEEG in Japan.
Business WirePoxel Announces Upcoming Participation at the JMP Securities Life Science Conference
LYON, France, May 11, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the JMP Securities Life Science Conference, to be held in New York, NY, Monday, May 15, and Tuesday, May 16, 2023.
Business WirePoxel Announces Availability of the 2022 Universal Registration Document and Provides Update on Accounts Settlement
LYON, France, May 03, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2022 has been filed with the French market authority (Autorité des Marchés Financ
Business WirePoxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted for Oral Presentation
LYON, France, April 20, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that nine abstracts based on Imeglimin Phase 2b and Phase 3 clinical trials have been accepted for oral presentations at the 66th Annual Meeting of the Japanese Diabe
Business WirePoxel Reports Financial Results for Full Year 2022 and Provides Corporate Update
LYON, France, March 23, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its results for the year ended December 31, 2022 and provided a corporate update.
Business WirePoxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
LYON, France, March 23, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that is has finalized (1) agreements with its lenders to restructure its existing debt obligations and (2) a new equity-linked financing with IRIS with an initial drawdown of EUR 3
Business WirePoxel will Report its 2022 Full Year Results on March 23, 2023
LYON, France, March 22, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced it will report its 2022 Full year results on March 23, 2023, before market opening.
Business WirePoxel to Report its 2022 Full Year Results by the End of March 2023
LYON, France, March 22, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that it will report its 2022 full year results by the end of March 2023.
Business WirePoxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event
LYON, France, March 15, 2023--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023.
Business WirePoxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology
LYON, France, March 07, 2023--Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced publication in Journal of Hepatology of positive results for DESTINY-1 (Deuterium-stabilized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), a 36-week dose-ranging Phase
Business WirePoxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
LYON, France, March 01, 2023--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-acti
Business WirePoxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update
LYON, France, February 15, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2022.
Business WirePoxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
LYON, France, January 25, 2023--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD). The decision follows a positive opinion from the Committ
Business WirePoxel Announces Upcoming Participation at Investor Conferences
LYON, France, January 04, 2023--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its upcoming participation at conferences organized by Oddo BHF and Degroof Petercam to be held in January 2023.
Business WirePoxel Announces its Financial Calendar for 2023
LYON, France, January 03, 2023--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023.
Business WirePoxel Announces Drawdown of the Remaining Two Tranches of its Equity-linked Financing Facility and Provides Corporate Update
LYON, France, December 22, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced the drawdown of the remaining two tranches of the convertible bonds as part of the equity-linked financing facility with Iris Capital Investment (IRIS) representing a total of EUR 2 million.
Business WirePoxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022
LYON, France, November 08, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2022.
Business WirePoxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) were presented during the late-breaking session at The Liver Meeting® 2022, hosted by the American Association for the Study
Business WirePoxel Announces Upcoming Participation at the Jefferies London Healthcare Conference
LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.
Business WirePoxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference
LYON, France, October 13, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it is presenting at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference on Monday, October 17th, 2022 at 10:00 am ET (4:00 pm CEST). Thomas Kuhn, CEO of Poxel, and other members
Business WirePoxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
LYON, France, October 12, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that its late-breaking abstract describing the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) has been selected for an oral presentation at The Liver Meeting® 2022, hosted by the A
Business WireAvailability of Poxel's 2022 Half-Year Financial Report
LYON, France, October 04, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022.
Business WirePoxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
LYON, France, October 03, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL7